← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
126	GMDA 126 DELISTED Gamida Cell Ltd. Ordinary Shares GMDA	–	–	–	–
127	127 Corgi Genomics & Precision Medicine ETF GNMX $1.61M	–	–	–	–
128	128 Global X Genomics & Biotechnology ETF GNOM $95.3M	–	–	–	–
129	129 Genenta Science GNTA $31.8M	–	–	–	–
130	130 GRAIL Inc GRAL $5.33B	–	–	–	–
131	GRCL 131 DELISTED Gracell Biotechnologies Inc. American Depositary Shares GRCL	–	–	–	–
132	GRML 132 Greenland Mines Ltd GRML $84M	–	–	–	–
133	GTH 133 DELISTED Genetron Holdings Limited ADS GTH	–	–	–	–
134	134 Fractyl Health GUTS $22.4M	–	–	–	–
135	135 Franklin Genomic Advancements ETF HELX $28.9M	–	–	–	–
136	136 iShares Genomics Immunology and Healthcare ETF IDNA $305M	–	–	–	–
137	137 Immix Biopharma IMMX $675M	–	–	–	–
138	138 Immatics IMTX $1.02B	–	–	–	–
139	139 IN8bio INAB $10.9M	–	–	–	–
140	140 MiNK Therapeutics INKT $48.5M	–	–	–	–
141	141 INmune Bio INMB $44.1M	–	–	–	–
142	142 Century Therapeutics IPSC $259M	–	–	–	–
143	KRBP 143 DELISTED Kiromic BioPharma, Inc. Common Stock KRBP	–	–	–	–
144	144 Korro Bio KRRO $130M	–	–	–	–
145	145 Kyverna Therapeutics KYTX $354M	–	–	–	–
146	146 Legend Biotech LEGN $3.6B	–	–	–	–
147	LGVN 147 Longeveron LGVN $4.5M	–	–	–	–
148	148 Lunai Bioworks LNAI $3.54M	–	–	–	–
149	LOGC 149 DELISTED LogicBio Therapeutics, Inc. Common Stock LOGC	–	–	–	–
150	150 Lexeo Therapeutics LXEO $224M	–	–	–	–